Biotech Startups

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children. Its initial focus is on neurometabolic and urea cycle disorders, including ornithine transcarbamylase (OTC) deficiency.

1 investor

IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer. The company operates through independently financed R&D subsidiaries, each advancing programs aimed at key control nodes of innate immunity such as NLRP3 and cGAS/STING.

1 investor

IFP Labs operates an integrated network of accredited analytical laboratories in Germany and the UK providing food safety testing, contaminant analysis, and regulatory compliance services. Services span chemical, physical, and microbiological testing for food, feed, water, environmental, and pharmaceutical samples, including nutritional profiling, allergen testing, and label compliance.

1 investor

Galenico is a CDMO (contract development and manufacturing organization) that develops and produces liquid, semi-solid, and solid pharmaceutical forms, covering formulation development, stability studies, manufacturing, filling, and packaging. It serves the medical device, cosmetics, and food supplement sectors, operating under Good Manufacturing Practices with production based in Portugal.

1 investor

Igea Medical develops and manufactures medical devices that use reversible electroporation to treat tumors (electrochemotherapy) and vascular malformations (electrosclerotherapy). The company sells and rents its devices to healthcare providers, based in Italy.

1 investor

IGNAE produces a regenerating body oil containing botanical actives and oils designed for skin hydration, collagen stimulation, and repair. The product targets consumers seeking premium skincare solutions for body care.

1 investor

Precision oncology company developing targeted therapeutics with companion diagnostics; IPO'd in 2014, acquired by Roche in 2018.

1 investor

IGS develops imaging and visualization technology based on inverse scattering theory to enable observation of previously invisible structures and phenomena. The company applies this core technology to solve problems in medical imaging, energy, infrastructure, and security sectors.

1 investor

Iksuda develops antibody-drug conjugates (ADCs) with enhanced tumor specificity for treating difficult-to-treat cancers. The company designs class-leading ADC therapeutics incorporating novel payloads and platform technologies optimized for anti-cancer efficacy and patient safety.

1 investor

ILiAD Biotechnologies is a clinical-stage biotechnology company developing vaccines and treatments for disease caused by Bordetella pertussis, with a lead candidate, BPZE1, a next-generation pertussis vaccine that has completed four Phase 2 clinical trials. It operates a wholly-owned subsidiary, BioLyo Technologies, a contract development and manufacturing organization for live bacterial products based in Ghent, Belgium.

1 investor

Ilico Genetics develops a blood-based molecular test for the early detection of gastric cancer using methylated DNA markers, designed to identify disease years before traditional methods. The company serves gastroenterologists and patients in the oncology diagnostics space, with a platform technology applicable to precision medicine and disease prevention.

1 investor

1 investor

Illumacell is a medtech company developing photodynamic therapy (PDT) treatments for cancer, including solid tumors, with preclinical research showing tumor reduction in animal models. It works on integrating light-based cancer therapies with traditional oncology treatments.

1 investor

Illumen Therapeutics is a biotech company developing first-in-class PARN inhibitor drugs that increase functional p53, a tumor suppressor, as a treatment for aggressive cancers. Its drug development focuses on targeting p53 dysregulation to improve cancer patient survival.

1 investor

Illuminare Bio develops Illuminare-1, a fluorescent imaging agent that makes peripheral nerves visible during surgery to help surgeons avoid nerve injury. The product is administered intravenously pre-operatively and works with standard surgical equipment across multiple procedure types including prostatectomy, mastectomy, hernia repair, and spinal surgery.

1 investor

1 investor

ImageCyte develops precision nanowell plate technology that prepares cells, organoids, and model organisms for imaging, aiming to improve imaging quality, reproducibility, and throughput. Its tools serve cell research and biological discovery workflows, focusing on the physical interface between samples and existing imaging instrumentation.

1 investor

Imagene develops AI-based oncology intelligence that turns cancer data into insights to support patient care and drug development. It serves the biotech and clinical oncology market, working with scientists, physicians, and therapy developers.

1 investor

Imagene Labs provides a cloud-based genetic analytics platform for healthcare services and wellness brands that delivers personalized product recommendations based on customers' DNA analysis using ethnically-relevant reference datasets. The platform covers traits including aging, fitness, nutrition, skin health, and children's health, and is compliant with Singapore's data protection standards.

1 investor

1 investor

1 investor

IMAI develops 3D histology technology for early and accurate diagnosis of cancer to improve therapeutic outcomes and patient care in oncology.

1 investor

Imbed Biosciences is a medical device company that develops SAMatrix, an ultra-thin, fully synthetic bioresorbable wound matrix that integrates antimicrobial silver and non-opioid pain agents (lidocaine) for treating chronic and acute wounds such as ulcers, surgical, traumatic, and burn wounds. Its product portfolio includes Surgaflex, Pelashield, and Microlyte, along with PainGuard variants.

1 investor

Translating cellular metabolism science into medicines for patients with limited treatment options.

1 investor